Key result
Newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban provide alternative therapeutic options to traditional anticoagulants for the long-term treatment of pulmonary embolism.
This review provides an overview of anticoagulant options, including newer oral agents, for the treatment of pulmonary embolism and venous thromboembolism.
Supports newer OACs as alternatives for long-term PE; leaves open need for comparative trials.
Warfarin, unfractionated heparin (UFH), and low-molecular-weight heparins are anticoagulants that have been used for treatment of pulmonary embolism. Currently approved drugs for treatment of venous thromboembolism include UFH, enoxaparin, dalteparin, fondaparinux, warfarin, and rivaroxaban. The advent of newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban has provided us with alternative therapeutic options for long-term anticoagulation. This article will give an overview of the various anticoagulant drugs, use in various clinical scenarios, data supporting their clinical use, and recommendations regarding duration of anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Harikrishnan et al. (2013) conducted a review in Pulmonary embolism. Anticoagulant drugs was evaluated. Newer oral anticoagulants such as rivaroxaban, dabigatran, and apixaban provide alternative therapeutic options to traditional anticoagulants for the long-term treatment of pulmonary embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: